• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

急性心肌梗死患者组织型纤溶酶原激活物的不良反应：真实世界和药物警戒数据库分析。

Adverse events of tissue plasminogen activators in acute myocardial infarction patients: a real-world and pharmacovigilance database analysis.

机构信息

Chongqing Key Laboratory of Emergency Medicine, Chongqing Emergency Medical Center/Chongqing University Central Hospital, School of Medicine, Chongqing University, Chongqing, 400014, China.

Department of Critical Care Medicine, Chongqing University Central Hospital, Chongqing, 400014, China.

出版信息

BMC Cardiovasc Disord. 2024 Aug 23;24(1):441. doi: 10.1186/s12872-024-04121-5.

DOI:10.1186/s12872-024-04121-5
PMID:39179962
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11342586/
Abstract

BACKGROUND

Tissue plasminogen activator (tPA) is recommended as the preferred thrombolytic therapy for acute myocardial infarction (AMI). This study aimed to explore tPA-related adverse events (AEs) reported in the United States Food and Drug Administration Adverse Event Reporting System (FAERS), assess the potential safety of three preferred tPA therapies for treating AMI, and provide guidance for selecting tPA for prehospital thrombolysis.

METHOD

Four algorithms, including ROR, PRR, BCPNN, and MGPS, were used to quantify the signals of Tenecteplase, Reteplase, and Alteplase related AEs and compare the differential degrees of the three tPA-associated AEs in the actual data.

RESULT

We detected 18 signals of Tenecteplase-induced AE, 29 signals of Reteplase-induced AE, and 22 signals of Alteplase-induced AE. Among the three drugs, Tenecteplase had the highest signal intensity for intracranial hemorrhage-related AE, followed by Alteplase. Besides, Reteplase had the highest signal intensity for procedure-related AE and Alteplase had the highest signal intensity for arrhythmia-related AE. The time-onset analysis indicates that we should be vigilant for AEs, especially within the first week and the first 1-2 days after medication.

CONCLUSION

This study identified and compared the signals of AE related to Tenecteplase, Reteplase, and Alteplase in AMI patients.

摘要

背景

组织型纤溶酶原激活剂（tPA）被推荐为急性心肌梗死（AMI）的首选溶栓治疗药物。本研究旨在探讨美国食品和药物管理局不良事件报告系统（FAERS）中报告的与 tPA 相关的不良事件（AE），评估三种治疗 AMI 的首选 tPA 疗法的潜在安全性，并为选择 tPA 进行院前溶栓治疗提供指导。

方法

使用 ROR、PRR、BCPNN 和 MGPS 四种算法对 Tenecteplase、Reteplase 和 Alteplase 相关 AE 的信号进行量化，并比较三种 tPA 相关 AE 在实际数据中的差异程度。

结果

我们检测到 18 个 Tenecteplase 诱导的 AE 信号、29 个 Reteplase 诱导的 AE 信号和 22 个 Alteplase 诱导的 AE 信号。在这三种药物中，Tenecteplase 引起的脑出血相关 AE 信号强度最高，其次是 Alteplase。此外，Reteplase 引起的与操作相关的 AE 信号强度最高，而 Alteplase 引起的心律失常相关 AE 信号强度最高。时间起始分析表明，我们应该警惕 AE，尤其是在用药后第一周和前 1-2 天。

结论

本研究确定并比较了 AMI 患者中与 Tenecteplase、Reteplase 和 Alteplase 相关的 AE 信号。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1331/11342586/455ffcba1f57/12872_2024_4121_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1331/11342586/7f5bdb89e87c/12872_2024_4121_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1331/11342586/159380c5ab73/12872_2024_4121_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1331/11342586/bd889b60063a/12872_2024_4121_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1331/11342586/455ffcba1f57/12872_2024_4121_Fig4_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1331/11342586/7f5bdb89e87c/12872_2024_4121_Fig1_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1331/11342586/159380c5ab73/12872_2024_4121_Fig2_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1331/11342586/bd889b60063a/12872_2024_4121_Fig3_HTML.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1331/11342586/455ffcba1f57/12872_2024_4121_Fig4_HTML.jpg

相似文献

1
Adverse events of tissue plasminogen activators in acute myocardial infarction patients: a real-world and pharmacovigilance database analysis.急性心肌梗死患者组织型纤溶酶原激活物的不良反应：真实世界和药物警戒数据库分析。
BMC Cardiovasc Disord. 2024 Aug 23;24(1):441. doi: 10.1186/s12872-024-04121-5.
2
Comparing adverse events of tenecteplase and alteplase: a real-world analysis of the FDA adverse event reporting system (FAERS).比较替奈普酶和阿替普酶的不良事件：对美国食品药品监督管理局不良事件报告系统（FAERS）的真实世界分析。
Expert Opin Drug Saf. 2024 Feb;23(2):221-229. doi: 10.1080/14740338.2023.2245745. Epub 2023 Aug 18.
3
Making a case for the right '-ase' in acute ischemic stroke: alteplase, tenecteplase, and reteplase.为急性缺血性脑卒中选择正确的“酶”-阿替普酶、替奈普酶和瑞替普酶。
Expert Opin Drug Saf. 2019 Feb;18(2):87-96. doi: 10.1080/14740338.2019.1573985.
4
Choosing the Correct "-ase" in Acute Ischemic Stroke: Alteplase, Tenecteplase, and Reteplase.急性缺血性卒中中正确选择“-ase”：阿替普酶、替奈普酶和瑞替普酶。
Adv Emerg Nurs J. 2019 Jul/Sep;41(3):271-278. doi: 10.1097/TME.0000000000000254.
5
Fibrin specificity and procoagulant effect related to the kallikrein-contact phase system and to plasmin generation with double-bolus reteplase and front-loaded alteplase thrombolysis in acute myocardial infarction.在急性心肌梗死中，与激肽释放酶 - 接触相系统以及双推注瑞替普酶和前端负荷阿替普酶溶栓时纤溶酶生成相关的纤维蛋白特异性和促凝血作用。
Am J Cardiol. 2000 Aug 1;86(3):263-8. doi: 10.1016/s0002-9149(00)00911-5.
6
Off-target effects of thrombolytic drugs: apolipoprotein A-I proteolysis by alteplase and tenecteplase.溶栓药物的非靶效应：阿朴脂蛋白 A-I 被组织型纤溶酶原激活物和替奈普酶水解。
Biochem Pharmacol. 2013 Feb 15;85(4):525-30. doi: 10.1016/j.bcp.2012.11.023. Epub 2012 Dec 5.
7
Randomized comparison of coronary thrombolysis achieved with double-bolus reteplase (recombinant plasminogen activator) and front-loaded, accelerated alteplase (recombinant tissue plasminogen activator) in patients with acute myocardial infarction. The RAPID II Investigators.双推注瑞替普酶（重组纤溶酶原激活剂）与前负荷加速阿替普酶（重组组织型纤溶酶原激活剂）用于急性心肌梗死患者冠状动脉溶栓的随机对照比较。RAPID II研究组。
Circulation. 1996 Sep 1;94(5):891-8. doi: 10.1161/01.cir.94.5.891.
8
Time to treatment and cost of thrombolysis: a multicenter comparison of tPA and rPA.溶栓治疗时间及费用：tPA与rPA的多中心比较
J Thromb Thrombolysis. 2000 Apr;9(3):303-8. doi: 10.1023/a:1018797411812.
9
Patency trials with reteplase (r-PA): what do they tell us?瑞替普酶（r-PA）通畅性试验：它们告诉了我们什么？
Am J Cardiol. 1996 Dec 19;78(12A):16-9. doi: 10.1016/s0002-9149(96)00738-2.
10
Absence of paradoxical thrombin activation by fibrin-specific thrombolytics in acute myocardial infarction: comparison of single-bolus tenecteplase and front-loaded alteplase.纤维蛋白特异性溶栓剂在急性心肌梗死中无反常凝血酶激活：单次推注替奈普酶与先予负荷量阿替普酶的比较
Thromb Res. 2002 Apr 15;106(2):113-9. doi: 10.1016/s0049-3848(02)00084-1.

引用本文的文献

1
Analysis of hemorrhagic transformation and intracerebral hemorrhage under combination therapy with alteplase and antiplatelets or anticoagulants, using the Japanese Adverse Drug Event Report database.利用日本药品不良事件报告数据库，分析阿替普酶与抗血小板药物或抗凝剂联合治疗下的出血性转化和脑出血情况。
PLoS One. 2025 Aug 18;20(8):e0329378. doi: 10.1371/journal.pone.0329378. eCollection 2025.

本文引用的文献

1
Adverse events in patients with advanced urothelial carcinoma treated with erdafitinib: a retrospective pharmacovigilance study.使用厄达替尼治疗的晚期尿路上皮癌患者的不良事件：一项回顾性药物警戒研究。
Front Pharmacol. 2023 Nov 21;14:1266890. doi: 10.3389/fphar.2023.1266890. eCollection 2023.
2
Application and risk prediction of thrombolytic therapy in cardio-cerebrovascular diseases: a review.溶栓治疗在心血管疾病中的应用及风险预测：综述
Thromb J. 2023 Sep 4;21(1):90. doi: 10.1186/s12959-023-00532-0.
3
2023 ESC Guidelines for the management of acute coronary syndromes.
2023年欧洲心脏病学会急性冠状动脉综合征管理指南。
Eur Heart J. 2023 Oct 12;44(38):3720-3826. doi: 10.1093/eurheartj/ehad191.
4
Cardiovascular toxicities following the use of tyrosine kinase inhibitors in hepatocellular cancer patients: a retrospective, pharmacovigilance study.酪氨酸激酶抑制剂在肝癌患者中的应用所导致的心血管毒性：一项回顾性、药物警戒学研究。
Expert Opin Drug Saf. 2024 Mar;23(3):287-296. doi: 10.1080/14740338.2023.2251398. Epub 2023 Aug 29.
5
Is There a Risk for Semaglutide Misuse? Focus on the Food and Drug Administration's FDA Adverse Events Reporting System (FAERS) Pharmacovigilance Dataset.司美格鲁肽存在滥用风险吗？聚焦美国食品药品监督管理局不良事件报告系统（FAERS）的药物警戒数据集。
Pharmaceuticals (Basel). 2023 Jul 11;16(7):994. doi: 10.3390/ph16070994.
6
Biosimilar Tenecteplase Versus Alteplase in Acute Ischemic Stroke: A Real World Study.生物类似药替奈普酶与阿替普酶治疗急性缺血性卒中的真实世界研究
Ann Indian Acad Neurol. 2023 Jan-Feb;26(1):54-58. doi: 10.4103/aian.aian_754_22. Epub 2023 Jan 4.
7
Outcomes with IV tenecteplase and IV alteplase for acute ischemic stroke with or without thrombectomy in real-world settings in the United States.在美国现实环境中，静脉注射替奈普酶和静脉注射阿替普酶用于急性缺血性卒中（无论是否进行血栓切除术）的疗效。
J Stroke Cerebrovasc Dis. 2023 Feb;32(2):106898. doi: 10.1016/j.jstrokecerebrovasdis.2022.106898. Epub 2022 Dec 6.
8
Gastrointestinal adverse events associated with semaglutide: A pharmacovigilance study based on FDA adverse event reporting system.基于 FDA 不良事件报告系统的司美格鲁肽相关胃肠道不良事件的药物警戒研究。
Front Public Health. 2022 Oct 20;10:996179. doi: 10.3389/fpubh.2022.996179. eCollection 2022.
9
2022 ACC/AHA Key Data Elements and Definitions for Chest Pain and Acute Myocardial Infarction: A Report of the American Heart Association/American College of Cardiology Joint Committee on Clinical Data Standards.2022年美国心脏病学会/美国心脏协会胸痛和急性心肌梗死关键数据元素及定义：美国心脏协会/美国心脏病学会临床数据标准联合委员会报告
J Am Coll Cardiol. 2022 Oct 25;80(17):1660-1700. doi: 10.1016/j.jacc.2022.05.012. Epub 2022 Aug 30.
10
Tenecteplase in Pulmonary Embolism Patients: A Meta-Analysis and Systematic Review.替奈普酶用于肺栓塞患者：一项荟萃分析与系统评价
Front Med (Lausanne). 2022 Mar 31;9:860565. doi: 10.3389/fmed.2022.860565. eCollection 2022.